PubRank

Robert C Doebele

Author PubWeight™ 62.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014 6.95
2 Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011 6.69
3 Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015 6.28
4 Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010 3.30
5 Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011 2.88
6 Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012 2.66
7 Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012 2.47
8 Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol 2012 1.97
9 Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 2013 1.94
10 Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012 1.70
11 Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One 2010 1.69
12 Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013 1.63
13 Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1. J Biol Chem 2007 1.44
14 Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 2012 1.43
15 Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity 2003 1.43
16 ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res 2013 1.38
17 Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2012 1.31
18 Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017 0.99
19 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
20 Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin Lung Cancer 2013 0.95
21 Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer 2013 0.92
22 Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemother Pharmacol 2012 0.92
23 A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol 2014 0.90
24 Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book 2013 0.87
25 A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer. PLoS One 2012 0.81
26 Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR. J Thorac Oncol 2013 0.79
27 Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer 2013 0.78
28 Genetic testing for lung cancer: reflex versus clinical selection. J Clin Oncol 2011 0.78
29 Biomarkers are here to stay for clinical research and standard care. J Thorac Oncol 2010 0.78
30 The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol 2014 0.78
31 Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. Drugs 2013 0.78
32 Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer? Nat Rev Clin Oncol 2013 0.76
33 Rearranging Detection of Gene Rearrangements. J Thorac Oncol 2015 0.75
34 A time to test, a time to treat. J Thorac Dis 2012 0.75
35 Oncogenic fusions involving exon 19 of ALK. J Thorac Oncol 2012 0.75
36 Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. Arch Pathol Lab Med 2016 0.75